Tiago Fauth
Stock Analyst at Wells Fargo
(1.23)
# 3,324
Out of 4,829 analysts
131
Total ratings
30.77%
Success rate
-13.34%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Maintains: Overweight | $93 → $107 | $63.32 | +68.98% | 5 | Apr 30, 2025 | |
| UTHR United Therapeutics | Downgrades: Equal-Weight | $395 → $314 | $301.42 | +4.17% | 5 | Apr 25, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Overweight | $112 → $101 | $19.76 | +411.13% | 4 | Mar 21, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $275 → $287 | $251.15 | +14.27% | 5 | Mar 21, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Equal-Weight | $4 → $3 | $1.41 | +112.77% | 2 | Mar 4, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $28 → $26 | $13.65 | +90.48% | 6 | Feb 27, 2025 | |
| FOLD Amicus Therapeutics | Maintains: Overweight | $18 → $17 | $5.99 | +184.04% | 1 | Feb 20, 2025 | |
| INSM Insmed | Maintains: Overweight | $85 → $107 | $65.08 | +64.41% | 3 | Feb 19, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $14 → $11 | $1.15 | +856.52% | 2 | Jan 13, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $75 → $88 | $35.11 | +150.64% | 7 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.86 | +179.72% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $4.56 | +97.37% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $68 | $44.23 | +53.74% | 1 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $22 | $6.59 | +234.09% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $44.24 | +69.53% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $1.24 | +4,900.00% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $151.46 | -41.24% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $12.39 | +311.62% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $58.86 | +103.87% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $14.02 | -71.47% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.75 | +409.09% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $5.76 | +351.39% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $2.03 | +1,279.31% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $17.30 | +368.21% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.43 | +1,761.33% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.07 | +1,208.41% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $0.42 | +7,951.15% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $2.75 | +5,364.48% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $36.17 | -19.82% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.44 | +802.78% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $1.45 | +796.55% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $1.61 | +24.22% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $549.27 | -38.10% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $265.86 | -2.58% | 1 | Apr 28, 2021 |
Verona Pharma
Apr 30, 2025
Maintains: Overweight
Price Target: $93 → $107
Current: $63.32
Upside: +68.98%
United Therapeutics
Apr 25, 2025
Downgrades: Equal-Weight
Price Target: $395 → $314
Current: $301.42
Upside: +4.17%
Tectonic Therapeutic
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $19.76
Upside: +411.13%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $275 → $287
Current: $251.15
Upside: +14.27%
Pliant Therapeutics
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.41
Upside: +112.77%
Keros Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $13.65
Upside: +90.48%
Amicus Therapeutics
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $5.99
Upside: +184.04%
Insmed
Feb 19, 2025
Maintains: Overweight
Price Target: $85 → $107
Current: $65.08
Upside: +64.41%
Inozyme Pharma
Jan 13, 2025
Maintains: Overweight
Price Target: $14 → $11
Current: $1.15
Upside: +856.52%
Ultragenyx Pharmaceutical
Dec 20, 2024
Maintains: Overweight
Price Target: $75 → $88
Current: $35.11
Upside: +150.64%
Dec 20, 2024
Initiates: Overweight
Price Target: $8
Current: $2.86
Upside: +179.72%
Dec 20, 2024
Initiates: Overweight
Price Target: $9
Current: $4.56
Upside: +97.37%
Nov 26, 2024
Maintains: Overweight
Price Target: $56 → $68
Current: $44.23
Upside: +53.74%
Oct 16, 2024
Maintains: Overweight
Price Target: $11 → $22
Current: $6.59
Upside: +234.09%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $44.24
Upside: +69.53%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $1.24
Upside: +4,900.00%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $151.46
Upside: -41.24%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $12.39
Upside: +311.62%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $58.86
Upside: +103.87%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $14.02
Upside: -71.47%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.75
Upside: +409.09%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $5.76
Upside: +351.39%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $2.03
Upside: +1,279.31%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $17.30
Upside: +368.21%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.43
Upside: +1,761.33%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.07
Upside: +1,208.41%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $0.42
Upside: +7,951.15%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $2.75
Upside: +5,364.48%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $36.17
Upside: -19.82%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.44
Upside: +802.78%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $1.45
Upside: +796.55%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.61
Upside: +24.22%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $549.27
Upside: -38.10%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $265.86
Upside: -2.58%